Melanotan 2 10mg Bienestar

Melanotan-2 mechanism of action articulates four distinct biological pathways corresponding to the four activated melanocortin receptor subtypes, each localized in different tissues and mediating specific physiological effects.

First pathway, cutaneous pigmentation via MC1R on epidermal melanocytes. MC1R activation by MT-2 triggers an adenylate-cyclase-cAMP-PKA-CREB-MITF cascade culminating in transcriptional stimulation of the tyrosinase gene, key enzyme of melanogenesis. The result is differential switching between phaeomelanin (red/yellow pigment, weakly photoprotective) and eumelanin (brown/black pigment, strongly photoprotective), with progressive predominance of eumelanin in melanosomes transferred to keratinocytes. Induced photoprotection represents roughly SPF 3 to 5 equivalent, insufficient to replace classical solar protection but sufficient to reduce actinic erythema and UVB-induced DNA damage. Crucially, MC1R activation by MT-2 does not eliminate the need for UV exposure: final pigmentation results from synergy between MT-2 melanocyte stimulation and UV stimulation activating melanosome maturation and transfer.

Second pathway, sexual behavior via central MC3R and MC4R. MT-2 crosses the blood-brain barrier at therapeutic doses and activates MC3R and MC4R receptors expressed in the hypothalamus (paraventricular nucleus), locus coeruleus, and sacral spinal cord. This central activation triggers oxytocin release, dopamine in mesolimbic reward circuits, and stimulates the sacral parasympathetic system responsible for male erection and female lubrication. Wessells and colleagues (1998, Urology) documented durable spontaneous erections in 80% of men receiving 0.025 mg/kg MT-2 subcutaneously, with onset 30 to 90 minutes post-injection and duration of 2 to 4 hours. Female libidinal stimulation is also documented but less quantified than in men. This central melanocortin action is exactly that exploited by FDA-approved PT-141 Bremelanotide, with the difference that MT-2 combines this effect with pigmentation.

Third pathway, appetite modulation via hypothalamic MC4R. Activation of paraventricular nucleus MC4R neurons inhibits agouti-related peptide (AgRP) orexigenic signals and stimulates proopiomelanocortin (POMC) anorexigenic signals. Users frequently report significant appetite reduction within 1 to 2 hours following injection, with moderate weight loss documented over 2-to-4-week cycles. This anorexigenic effect is not the primary goal of MT-2 but constitutes a predictable side effect of the mechanism of action. MC4R polymorphisms being one of the most documented genetic causes of human obesity, this pathway is subject to active pharmaceutical research with molecules like Setmelanotide (Imcivree FDA 2020).

Fourth pathway, thermoregulation, inflammation, and exocrine functions via MC5R. MC5R is expressed on sweat, sebaceous, and exocrine glands, and in several immune populations. Its activation by MT-2 modulates thermoregulation, sebaceous production (sometimes associated with increased acne), and exerts anti-inflammatory action via cytokine regulation. This pathway is the least well-characterized of the melanocortin quartet but contributes to the overall MT-2 effect profile.

Scientific literature on Melanotan-2 is heterogeneous but solid on fundamental aspects. Founding work from the University of Arizona during the 1980s constitutes the base: Dorr and colleagues (1988) demonstrated directed synthesis of the cyclic peptide, Hadley and Hruby (1988, Experientia) characterized the compound's superpotency versus endogenous alpha-MSH (approximately 1000-fold more potent in vitro), and first human trials addressed skin cancer prevention.

Dorr and colleagues (1996, Life Sciences, 58:20 pages 1777-1784) conducted a phase I clinical trial with dose escalation on 23 healthy volunteers, documenting dose-dependent cutaneous pigmentation measured by colorimetry, with pigmentary effect onset from 0.25 mg/day over 10 days and plateau at 1 mg/day. Main documented adverse effects were nausea (dose-dependent, 80% of subjects at highest doses), facial flushing, and spontaneous erections in men. This study remains the worldwide reference on human MT-2 pharmacology.

Wessells and colleagues (1998, Urology, 52:6 pages 1076-1081) published the seminal study on MT-2 sexual effects in 10 men with psychogenic erectile dysfunction. Doses of 0.025 mg/kg subcutaneously, evaluation by nocturnal penile rigidometer. Results: 8 out of 10 men (80%) obtained durable spontaneous erections within 30 to 90 minutes, with mean duration of 3 hours. This study was the starting point of all subsequent pharmaceutical development around melanocortins and sexuality, culminating in PT-141 Bremelanotide FDA 2019 approval.

Diamond and colleagues (2004, J Sex Med) explored effects in women with HSDD (Hypoactive Sexual Desire Disorder), documenting improvement in sexual desire and satisfaction scores, paving the way for Palatin Technologies' RECONNECT studies leading to Vyleesi approval.

Hadley (1996, Annals NY Acad Sci) and Luger (2002, Am J Clin Dermatol) published integrative reviews on the entire melanocortin field, positioning MT-2 as a reference non-selective pharmacological tool versus more selective analogs like Melanotan-1 (Afamelanotide Clinuvel), PT-141 (Bremelanotide Palatin), and Setmelanotide (Rhythm Pharmaceuticals). Levine and colleagues (1991, Biochemistry) characterized cyclization chemistry and established the structural bases of superpotency.

Human pharmacokinetics: Ugwu and colleagues (1997) documented a plasma half-life of 33 hours after subcutaneous administration, exceptionally long for a peptide of this size, thanks to cyclization and D-substitution that resist plasma proteases. This unique pharmacokinetics explains why dosing protocols recommend initial daily doses then 2-to-3-times-weekly maintenance doses.

Safety alerts: several publications (Cardones 2009 Arch Dermatol, Cousen 2009 Clin Exp Dermatol, Ellis 2009 Br J Dermatol) reported cases of rapid darkening of atypical melanocytic nevi in non-medical MT-2 users, raising concern about a hypothetical promotion of existing undiagnosed melanomas. No prospective trial has confirmed a real increase in melanoma incidence, but caution is warranted in subjects bearing numerous nevi or atypical nevi. UK MHRA prohibited over-the-counter MT-2 sale in 2008 citing these safety signals.